2025-12-19 - Analysis Report
Okay, here's a comprehensive analysis of Eli Lilly and Co (LLY) based on the provided data:

**0) Overview:**

This report analyzes Eli Lilly and Co (LLY), comparing its performance against the S&P 500 (VOO). It covers return rates, alpha/beta analysis, recent stock fluctuations, market indicators, news & events, analyst opinions, and financial information.

**1) Return Rate Comparison:**

*   **Ticker:** LLY (Eli Lilly and Co) - A pharmaceutical company focused on developing and marketing medicines.
*   **LLY Cumulative Return:** 300.11%
*   **VOO (S&P 500) Cumulative Return:** 99.09%
*   **Divergence:** Current: 199.3, Relative Divergence: 82.6
    *   LLY has significantly outperformed the S&P 500, with a cumulative return three times higher.
    *   The divergence of 199.3 indicates a substantial difference in performance.
    *   The relative divergence of 82.6 suggests the current divergence is high relative to its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta | Cap(B) |
|------------|---------|---------|---------|------|--------|
| 2015-2017  | 11.0%   | 76.1%   | -17.0%  | -0.0 | 75.7   |
| 2016-2018  | 39.0%   | 68.9%   | 24.0%   | -0.0 | 103.7  |
| 2017-2019  | 41.0%   | 68.9%   | 19.0%   | 0.4  | 117.8  |
| 2018-2020  | 34.0%   | 79.8%   | 10.0%   | 0.4  | 151.4  |
| 2019-2021  | 53.0%   | 79.8%   | 7.0%    | 0.5  | 247.6  |
| 2020-2022  | 64.0%   | 79.8%   | 65.0%   | 0.4  | 328.0  |
| 2021-2023  | 125.0%  | 78.9%   | 124.0%  | 0.2  | 522.6  |
| 2022-2024  | 134.0%  | 81.2%   | 113.0%  | 0.2  | 692.1  |
| 2023-2025  | 191.0%  | 83.5%   | 128.0%  | 0.2  | 947.5  |

*   **CAGR (Compound Annual Growth Rate):**  CAGR has increased significantly in recent years, driven by positive results.
*   **MDD (Maximum Drawdown):** MDD indicates how much an investment could decline from peak to trough. LLY's MDD remains high, suggesting volatility.
*   **Alpha:** LLY has consistently delivered positive alpha, showing that it outperforms its benchmark. In the most recent years (2020-2025), the alpha has been exceptionally high, reflecting strong performance.
*   **Beta:** Beta is relatively low (around 0.2-0.5) in recent years, indicating lower volatility compared to the market.
*   **Cap(B) (Market Capitalization):** Market capitalization has grown substantially, indicating investor confidence and market recognition of LLY's value.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 1056.88
*   **Last Market Data:** {'price': 1056.88, 'previousClose': 1041.79, 'change': 1.45}
*   **5-day SMA:** 1048.53
*   **20-day SMA:** 1041.15
*   **60-day SMA:** 925.23

*   The stock price is above all three Simple Moving Averages (SMAs), indicating an upward trend. The 5-day SMA is above the 20-day SMA, which is also above the 60-day SMA, further confirming this trend.

**3) Market Indicators:**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment)
*   **RSI (Relative Strength Index):** 45.68 - indicates LLY is neither overbought nor oversold.
*   **PPO (Percentage Price Oscillator):** -0.41 - Indicates that the short-term moving average is slightly below the long-term moving average, potentially signaling a slight weakening in the short-term trend.
*   **Hybrid Signal:** Buy 100% of cash
*   **Recent (20 days) relative divergence change:** 10.1 (+): 단기상승 (short-term increase)
*   **Expected Return:** 51.6% - Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.
*   A significant price change indicates a fluctuation issue (sharp rebound, sharp decline).

**4) Recent News & Significant Events:**

*   **Weight-Loss Drug Dominance:** Bank of America highlights that the market isn't fully pricing in Eli Lilly's potential dominance in weight-loss drugs.
*   **Stock Performance vs. Nvidia:** Eli Lilly's stock has outperformed Nvidia in recent weeks, a noteworthy shift.
*   **Retatrutide Breakthrough:** Positive news regarding the weight loss drug Retatrutide from Eli Lilly.
*   **Dividend Increase:** Eli Lilly is among the healthcare giants that have recently raised dividends.
*   **Future Outlook:**  Analysis on where Eli Lilly will be in 10 years suggests a positive long-term view.
*   **Novo Nordisk Falling:** News mentioning Eli Lilly in the context of a decline in Novo Nordisk stock, potentially suggesting competitive dynamics in the market.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.70)
*   **Target Price:** Average: 1093.22, High: 1500.00, Low: 770.00
*   **Recent Rating Changes:** No recent rating changes mentioned.
    *   The consensus among analysts is "Buy," with a target price significantly above the current price, indicating potential upside.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-30 | 6.22  | 17.60 B$   |
| 2025-08-07 | 6.3   | 15.56 B$   |
| 2025-05-01 | 3.07  | 12.73 B$   |
| 2024-10-30 | 1.08  | 11.44 B$   |
| 2025-10-30 | 1.08  | 11.44 B$   |

*   Earnings per share (EPS) and revenue have shown significant growth over the past year. The most recent quarters (2025) indicate strong performance, with EPS consistently high.
*   The repeated "2025-10-30" date may indicate an error in the data. If the second instance should be "2024-10-30," it highlights the dramatic improvement in earnings over the past year.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.60B   | 82.91%        |
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |

*   Revenue has consistently increased over the past five quarters.
*   Profit margins are exceptionally high and relatively stable, indicating strong profitability and efficient operations.

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $23.79B   | 23.46%  |
| 2025-06-30   | $18.27B   | 30.98%  |
| 2025-03-31   | $15.76B   | 17.50%  |
| 2024-12-31   | $14.19B   | 31.07%  |
| 2024-09-30   | $14.24B   | 6.81%   |

*   Equity has increased substantially, reflecting the company's growing value.
*   Return on Equity (ROE) is high, indicating efficient use of shareholder equity to generate profits.

**7) Comprehensive Analysis:**

Eli Lilly (LLY) is exhibiting very strong performance and positive indicators across multiple fronts:

*   **Exceptional Growth:** LLY has significantly outperformed the S&P 500, with an impressive cumulative return. Its recent CAGR has been extraordinary.
*   **Strong Financials:** Revenue, profit margins, and ROE are all high and trending positively.
*   **Positive Market Sentiment:** Analyst consensus is "Buy," and market capitalization has grown substantially.
*   **Promising Pipeline:** News headlines highlight the potential of its weight-loss drugs and future outlook.
*   **Technical Indicators:** The stock price is above its moving averages, and while the RSI is neutral, the recent divergence suggests a short-term increase.
*   **Market Risk:** The MRI indicates a medium investment risk.

**Overall, Eli Lilly appears to be a strong investment opportunity, driven by its promising drug pipeline, strong financial performance, and positive market sentiment. The data suggests continued growth potential.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.